cangrelor: Clinical Trials

3 trials of cangrelor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 suspended. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Suspended 1

Follow cangrelor: new trials by email Literature Review of cangrelor trials Research Report on cangrelor

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
Cangrelor, best medical management - Acute Ischemia
Phase 3SuspendedFondation Ophtalmologique Adolphe de Rothschild3682022-03-022026-09-25
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
Cangrelor, clopidogrel, Placebo bolus & placebo infusion - Atherosclerosis, Acute Coronary Syndrome (ACS)
Phase 3TerminatedThe Medicines Company53642006-09-012014-05-05
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion - Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Phase 3TerminatedThe Medicines Company88822006-04-012014-05-08

Conditions studied

Acute Coronary Syndrome (2)  ·  Atherosclerosis (1)  ·  Myocardial Infarction (1)  ·  Non-ST Elevated Myocardial Infarction (1)  ·  ST Elevation Myocardial Infarction (1)

Sponsors

The Medicines Company (2)  ·  Fondation Ophtalmologique Adolphe de Rothschild (1)

Countries

United States (2)  ·  France (1)

Top investigators

Deepak L. Bhatt, MD (2)  ·  Robert A. Harrington, MD (2)  ·  Simona Skerjanec, PharmD (2)

Results publications

PMID 22305835, PMID 27902833, PMID 28382371, PMID 28988157, PMID 29632238, PMID 35196863, PMID 38551015, PMID 19915221, PMID 19915222